Drug intelligence / Profile preview

PRT-SCA2

Development stage: Preclinical
Lead developer: Prelude Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

PRT-SCA2 is a **small molecule inhibitor** of SMARCA2, developed by Prelude Therapeutics for the treatment of cancer. SMARCA2 is a chromatin remodeler from the SWI/SNF complex, often altered in certain cancers, and its inhibition is being explored as a targeted therapeutic strategy. The current development status of PRT-SCA2 is pending, with limited published clinical or preclinical data available. Its principal mechanism is presumed to be the selective inhibition of the SMARCA2 protein to modulate gene expression involved in tumor proliferation and survival[1].

Targets

SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily A member 2)

Beyond the preview

Go deeper on PRT-SCA2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT-SCA2.

Explore the full profile